C. Lewden, V. Bouteloup, D. Wit, and S. , All-cause mortality in treated HIV-infected adults with CD4 >/=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration, Int J Epidemiol, vol.41, pp.433-478, 2012.

M. T. May and S. M. Ingle, Life expectancy of HIV-positive adults: a review, Sex Health, vol.8, pp.526-559, 2011.

V. Hernando, S. Perez-cachafeiro, and C. Lewden, All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection, J Hepatol, vol.57, pp.743-51, 2012.

T. Y. Chen, E. L. Ding, S. Iii, G. R. Kim, and A. Y. , Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression, Clin Infect Dis, vol.49, pp.1605-1620, 2009.

P. Morlat, C. Roussillon, and S. Henard, Causes of death among HIV-infected patients in France in 2010 (national survey): trends since, AIDS, vol.28, pp.1181-91, 2000.

E. Rosenthal, C. Roussillon, and D. Salmon-ceron, Liver-related deaths in HIVinfected patients between, 1995.
URL : https://hal.archives-ouvertes.fr/hal-01939337

, Mortalite 2010 survey, HIV Med, vol.16, pp.230-239, 2015.

M. A. Loko, D. Salmon, and P. Carrieri, The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, BMC Infect Dis, vol.10, p.303, 2006.
URL : https://hal.archives-ouvertes.fr/pasteur-01070193

J. G. Mchutchison, E. J. Lawitz, and M. L. Shiffman, Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection, N Engl J Med, vol.361, pp.580-93, 2009.

V. Soriano, M. Puoti, and M. Sulkowski, Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel, AIDS, vol.21, pp.1073-89, 2007.

J. A. Mira, S. Garcia-rey, and A. Rivero, Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis, Clin Infect Dis, vol.55, pp.1719-1745, 2012.

M. Sulkowski, S. Pol, and J. Mallolas, Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial, Lancet Infect Dis, vol.13, pp.597-605, 2013.

C. Hezode, H. Fontaine, and C. Dorival, Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis, Gastroenterology, vol.147, pp.132-174, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01057763

L. Cotte, J. Braun, and C. Lascoux-combe, Telaprevir for HIV/hepatitis C viruscoinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial, Clin Infect Dis, vol.59, pp.1768-76, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01118447

P. Miailhes, C. Gilbert, and K. Lacombe, Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients, Liver Int, vol.35, pp.2090-2099, 2015.

D. Salmon, F. Bani-sadr, and C. Gilbert, HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients, J Clin Virol, vol.73, pp.32-37, 2015.

J. E. Arends, J. T. Van-der-meer, and D. Posthouwer, Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients, Neth J Med, vol.73, pp.324-354, 2015.

M. S. Sulkowski, S. Naggie, and J. Lalezari, Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection, JAMA, vol.312, pp.353-61, 2014.

J. M. Molina, C. Orkin, and D. M. Iser, Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, openlabel, non-randomised, phase 3 study, Lancet, vol.385, pp.1098-106, 2015.

D. L. Wyles, P. J. Ruane, and M. S. Sulkowski, Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1, N Engl J Med, vol.373, pp.714-739, 2015.

S. Naggie, C. Cooper, and M. Saag, Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1, N Engl J Med, vol.373, pp.705-718, 2015.

M. S. Sulkowski, J. J. Eron, and D. Wyles, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial, JAMA, vol.313, pp.1223-1254, 2015.

M. Winnock, F. Bani-sadr, and E. Pambrun, Factors associated with guidelinebased hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions, HIV Med, vol.14, pp.430-436, 2013.

, American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, Hepatology, vol.62, pp.932-54, 2015.

, European Association for the Study of the Liver. EASL recommendations on treatment of Hepatitis C 2015, J Hepatol, vol.63, pp.199-236, 2015.

O. Chazouillères, H. Fontaine, and B. Hanslik, Recommandations AFEF sur la prise en charge des hépatites virales C. Paris: Association Française pour l'Etude du Foie, 2015.

M. Rodriguez-torres, A. Gaggar, and G. Shen, Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV, J Acquir Immune Defic Syndr, vol.68, pp.543-552, 2015.

M. S. Sulkowski, I. M. Jacobson, and D. R. Nelson, Daclatasvir plus sofosbuvir for HCV infection, N Engl J Med, vol.370, pp.1560-1561, 2014.

V. Saxena, L. Nyberg, and M. Pauly, Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis, Hepatology, vol.62, pp.715-740, 2015.

M. Charlton, G. T. Everson, and S. L. Flamm, Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease, Gastroenterology, vol.149, pp.649-59, 2015.

A. J. Van-der-meer, B. J. Veldt, and J. J. Feld, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, Jama, vol.308, pp.2584-93, 2012.

B. N. Limketkai, S. H. Mehta, and C. G. Sutcliffe, Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/ HCV, JAMA, vol.308, pp.370-378, 2012.

M. B. Klein, K. C. Rollet-kurhajec, and E. E. Moodie, Mortality in HIV-hepatitis C coinfected patients in Canada compared to the general Canadian population, AIDS, vol.28, pp.1957-65, 2014.

J. Berenguer, F. X. Zamora, and A. Carrero, Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis, J Acquir Immune Defic Syndr, vol.66, pp.280-287, 2014.

A. Group, ;. D. Salmon, F. Dabis, L. Wittkop, L. Esterle et al.,

A. Pitié-salpétrière, Virologie: S. Fourati

A. Pitié-salpétrière,

A. Saintemarguerite, Virologie: C. Tamalet)

A. Tenon, Virologie: C. Le Pendeven

, Toulouse (Maladies Infectieuses et Tropicales: B. Marchou; Hépato-gastro-entérologie

. Anatomo-pathologie, Virologie: F. Larroquette

, DAAs in HIV/HCV-Coinfected Cirrhotic Patients ? CID, vol.2016, p.769

, Virologie: C. Partouche)

A. Avicenne,

:. M. Anatomo-pathologie and . Ziol, Virologie: Y. Baazia

. Anatomo-pathologie, Virologie: F. Nicot

A. , Virologie: G. Alexandre

A. Saint-louis,

, Virologie: P. Palmer)

A. Saint-antoine, ;. K. Lacombe, P. ;. Campa, . Girard, :. D. Anatomo-pathologie et al., Maladies Infectieuses et Tropicales

A. Bicêtre,

, Maladies Infectieuses: D. Vittecoq

A. Necker, Maladies Infectieuses et Tropicales: O. Lortholary, C. Duvivier, M. Shoai-Tehrani: Virologie: A. Mélard)

M. Infectieuses, D. Tropicales, A. Neau, E. Ochoa, S. Blanchard et al.,

:. P. Anatomopathologie and . Bioulac-sage, Virologie: P. Trimoulet, S. Reigadas

P. Morlat, D. Lacoste, F. Bonnet, N. Bernard, M. Bonarek-hessamfar et al.,

:. P. Anatomo-pathologie and . Bioulac-sage, Virologie: P. Trimoulet, S. Reigadas

. Hôpital-du-haut-levêque, :. J. Bordeaux-(médecine-interne, J. F. Pellegrin, E. Viallard, C. Lazzaro et al.,

F. Hôpital, :. D. Suresnes-(médecine-interne, C. Zucman, and . Majerholc, Virologie: F. Guitard)

A. Béclère, :. F. Clamart-(médecine-interne, J. Boué, I. Polo-devoto, V. Kansau et al., Virologie: C. Deback)

C. Mondor,

, Virologie: A. Rodallec

. Hôpital-de-la-croix-rousse, . Lyon-(maladies, . Infectieuses, :. P. Tropicales, D. Miailhes et al., Virologie: T. T. Le-Thi

. Chu-dijon, :. L. Dijon-(département-d'infectiologie, P. Piroth, M. Chavanet, M. Duong-van-huyen et al., Simonet-Lann, D. CroisierBertin

C. Perpignan, Perpignan (Maladies infectieuses et tropicales: H. Aumaître)

. Chu-robert-debré, Médecine interne, maladies infectieuses et immunologie clinique

C. Strasbourg, (. Rey, M. Partrisiani, P. Gautner, and M. L. Batard,